

Malaria vaccines indicator

Safety of the intervention

Type, including severity, consequences and frequency of short- and long-term adverse events following vaccination

Both recommended vaccines (RTS,S/AS01 and R21/Matrix-M) have a good safety profile. There is a small risk of febrile seizures within seven days (mainly within 2-3 days) of vaccination. ¹

Malaria vaccines should not be given to anyone who has experienced a severe allergic reaction after a previous hepatitis B vaccine dose, malaria vaccine dose or malaria vaccine component.

RTS,S/AS01 can be given to children with HIV infection. A trial of R21/Matrix-M in HIV-positive infants is ongoing and data are not yet available.

Sources

1.
World Health Organization (2024). Malaria vaccines: WHO position paper, May 2024. Wkly Epidemiol Rec. 99(19):225–248 (<https://www.who.int/publications/i/item/who-wer-9919-225-248>, accessed 13 May 2026).